Outcome of Parkinson's Disease Patients Affected by COVID-19.

Antonini, Angelo; Leta, Valentina; Teo, James; Chaudhuri, K Ray

Antonini, Angelo; Leta, Valentina; Teo, James; Chaudhuri, K Ray.

Antonini A; Parkinson and Movement Disorders Unit, University of Padua, Padua, Italy.
Leta V; King's College London, Institute of Psychiatry, Psychology & Neuroscience, London, United Kingdom.
Teo J; Parkinson's Foundation Centre of Excellence, King's College Hospital, London, United Kingdom.
Chaudhuri KR; King's College London, Institute of Psychiatry, Psychology & Neuroscience, London, United Kingdom.

Mov Disord ; 35(6): 905-908, 2020 06.

Article in English | MEDLINE | ID: covidwho-626697

Subject(s)

Betacoronavirus/pathogenicity; Carbidopa/therapeutic use; Coronavirus Infections/drug therapy; Levodopa/therapeutic use; Parkinson Disease/drug therapy; Pneumonia, Viral/drug therapy; Aged; Aged, 80 and over; Betacoronavirus/drug effects; COVID-19; Coronavirus Infections/complications; Female; Humans; Male; Pandemics; Parkinson Disease/complications; Pneumonia, Viral/complications; SARS-CoV-2; Treatment Outcome

Keywords

COVID-19; Parkinson's disease; SARS-CoV-2

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Parkinson Disease / Pneumonia, Viral / Carbidopa / Levodopa / Coronavirus Infections / Betacoronavirus Type of study: Prognostic study Topics: Long Covid Limits: Aged / Female / Humans / Male Language: English Journal: Mov Disord Journal subject: Neurology Year: 2020 Document Type: Article Affiliation country: Mds.28104

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google